Regulatory approval

Published by the Health Service Executive. Approved

Treatment of patients with relapsed/refractory low grade B cell Non Hodgkin's lymphoma (NHL).

This is written in the approval document.

Reimbursement

Hospital

Citation

riTUXimab, Cyclophosphamide, vinCRIStine and prednisoLONE R-CVP Therapy-21 days, 2023, version number 3a, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://assets.hse.ie/media/documents/293_v3a_R_CVP.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2017-03-08	Health Service Executive	Indication approved for reimbursement.